Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mechanisms Underlying the Greater Efficacy of Robot-Assisted Gait Rehabilitation Versus Conventional Therapy Combined With Botulinum Toxin Injection of the Triceps Surae in Individuals With Chronic Post-Stroke Impairments (NEUROBOST)

16. november 2026 oppdatert av: COTINAT Maeva, Aix Marseille Université

Stroke is a leading cause of long-term disability in adults. Many people who have had a stroke continue to experience difficulty walking because of muscle weakness and spasticity, which can limit their mobility and quality of life.

Botulinum toxin injections are commonly used to reduce spasticity in specific muscles, such as the calf muscles. Rehabilitation is then used to improve walking ability. Robot-assisted gait rehabilitation allows patients to practice walking intensively and repeatedly, with assistance adjusted to their needs. Previous research from our team has shown that robot-assisted gait rehabilitation may improve walking ability more than conventional physical therapy when combined with botulinum toxin injections.

The purpose of this study is to better understand why robot-assisted gait rehabilitation may be more effective than conventional gait rehabilitation after botulinum toxin treatment in people with chronic stroke. The study will examine changes in walking patterns, muscle activity, and brain activity during and after rehabilitation. Brain activity and brain connections will be assessed using non-invasive methods, including functional near-infrared spectroscopy (fNIRS), electroencephalography (EEG), and magnetic resonance imaging (MRI).

The study may help identify how the brain and body adapt to rehabilitation and may contribute to developing more personalized rehabilitation programs for people living with long-term effects of stroke.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Stroke is a major cause of acquired motor disability in adults. In the chronic phase after stroke, persistent motor impairment is frequently associated with spastic paresis, altered motor control, and maladaptive or compensatory reorganization of the central nervous system. Spasticity may contribute substantially to gait impairment and reduced mobility, thereby affecting functional independence and quality of life.

Botulinum toxin type A (BoNT-A) is an established treatment for focal spasticity after stroke. Intramuscular injection into the triceps surae reduces excessive muscle activity through its action at the neuromuscular junction and can temporarily improve the mechanical conditions for walking. In addition to these peripheral effects, BoNT-A may also indirectly influence central motor networks by modifying proprioceptive and afferent sensory input, potentially promoting cortical reorganization.

Following BoNT-A injection, intensive rehabilitation is required to optimize functional recovery. Robot-assisted gait rehabilitation provides a means of delivering intensive, repetitive, task-specific gait practice, with partial body-weight support and adjustable motor assistance. This approach may allow patients to perform a greater number of gait cycles and to train at higher walking speeds than conventional gait therapy. Previous studies have suggested that robot-assisted gait rehabilitation may improve gait performance, propulsion, gait symmetry, and motor coordination. In a previous study conducted by our research team, robot-assisted gait rehabilitation performed after BoNT-A injection into the triceps surae resulted in a significantly greater improvement in 6-minute walk distance than conventional gait rehabilitation.

The present study aims to investigate the neurophysiological and biomechanical mechanisms underlying the potentially greater benefit of robot-assisted gait rehabilitation compared with conventional gait rehabilitation following BoNT-A treatment in individuals with chronic stroke.

The study will characterize changes in gait performance and gait biomechanics, including spatiotemporal parameters, lower-limb joint kinematics, ground reaction forces, propulsion, and muscle activation patterns. These measurements will be used to determine whether specific changes in gait mechanics and neuromuscular coordination are associated with the greater improvement observed following robot-assisted rehabilitation.

In parallel, the study will investigate changes in brain activity and functional organization associated with rehabilitation. Functional near-infrared spectroscopy (fNIRS) will be used to assess cortical activation during walking. Electroencephalography (EEG) will be used to characterize cortical electrical activity and functional connectivity, with particular attention to changes in frontoparietal and motor networks. Resting-state functional magnetic resonance imaging (fMRI) and diffusion MRI will be used to assess functional and structural brain connectivity, respectively, as well as lesion characteristics and the organization of motor networks.

A particular focus will be placed on changes in the lateralization and organization of motor cortical activity following rehabilitation. The study will test the hypothesis that robot-assisted gait rehabilitation induces more effective neuroplastic adaptations than conventional gait rehabilitation after BoNT-A treatment. These adaptations are expected to involve a shift toward more efficient recruitment and functional organization of ipsilesional motor regions, together with changes in interhemispheric and network-level connectivity.

The study will also investigate whether central effects of BoNT-A can be detected through changes in cortical activity, including modifications of ipsilesional posterior parietal cortex activity previously reported after BoNT-A treatment.

By combining complementary neurophysiological, neuroimaging, biomechanical, and clinical measures, the study aims to identify mechanisms associated with improved walking recovery after BoNT-A combined with robot-assisted gait rehabilitation. An additional objective is to identify quantitative biomarkers that may help predict which individuals are most likely to benefit from this rehabilitation strategy and, ultimately, contribute to more individualized rehabilitation approaches for people with chronic post-stroke motor impairment.

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults with hemiparesis.
  • Affiliated with a national or public health insurance system.
  • Able and willing to provide written informed consent after receiving information about the purpose, procedures, and potential risks of the study.
  • At least 6 months after a unilateral stroke.
  • Presence of triceps surae spasticity causing impaired gait and treatment with botulinum toxin type A (BoNT-A) as part of routine care, with a stable dose for at least 2 treatment cycles.
  • Able to walk for 6 minutes; walking speed <0.8 m/s on the 10-Meter Walk Test.

Exclusion Criteria:

  • Cognitive impairment preventing the participant from providing informed consent.
  • Triceps surae spasticity >3/5 on the Modified Ashworth Scale.
  • Any contraindication to physical exercise, robot-assisted gait rehabilitation using the Lokomat, or MRI.
  • Claustrophobia or fear of confined spaces.
  • Individuals deprived of liberty by judicial or administrative decision, or under legal guardianship.
  • Inability to complete all study procedures.
  • Pregnancy, breastfeeding, or plans to become pregnant during the study period.
  • Concurrent participation in another research study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Robot-Assisted Gait Rehabilitation

Participants receive robot-assisted gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of intensive, repetitive gait training using a robotic device, with adjustable assistance and body-weight support as appropriate.

Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.

Andre navn:
  • EEG
  • fNIRS

The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.

Andre navn:
  • MR
  • Magnetisk resonansavbildning

Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.

Andre navn:
  • 6MWT

Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Andre navn:
  • MRC Scale

Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.

Andre navn:
  • BBS
Aktiv komparator: Conventional Gait Rehabilitation

Participants receive conventional gait rehabilitation following botulinum toxin type A injection into the triceps surae. The intervention consists of therapist-guided gait training and conventional physical therapy according to standard clinical practice.

Motor area connectivity during walking will be assessed using a combined functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG) system. Each fNIRS/EEG assessment will consist of three repetitions of a rest-task-rest block (30-60-30 seconds). During the task period, participants will walk overground along a walkway at a self-selected comfortable speed.

Andre navn:
  • EEG
  • fNIRS

The 3T MRI protocol will include an anatomical MRI scan to localize the stroke lesion and assess its size, a resting-state functional MRI (rs-fMRI) to characterize the resting-state functional connectome, and a diffusion-weighted MRI to characterize the structural connectome.

Andre navn:
  • MR
  • Magnetisk resonansavbildning

Participants will be asked to walk as far as possible for 6 minutes along a designated walking course at their self-selected pace. The total distance walked will be recorded as a measure of walking endurance and functional mobility.

Andre navn:
  • 6MWT

Muscle strength will be assessed using the Medical Research Council (MRC) scale. This clinical assessment grades muscle strength on a 0-to-5 scale, with higher scores indicating greater muscle strength.

Andre navn:
  • MRC Scale

Balance will be assessed using the Berg Balance Scale, a clinical assessment consisting of 14 functional tasks evaluating static and dynamic balance. Each item is scored from 0 to 4, with higher scores indicating better balance performance and a lower risk of falls.

Andre navn:
  • BBS

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Difference in the Lateralization Index of Nodal Degree in the Paracentral Lobules
Tidsramme: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

The primary outcome measure is the between-group difference in the organization of motor functional brain networks following botulinum toxin type A (BoNT-A) treatment of spasticity in the triceps surae, comparing robot-assisted gait rehabilitation with conventional gait rehabilitation.

At rest, functional brain network organization will be assessed using resting-state functional magnetic resonance imaging (rs-fMRI). The primary resting-state parameter will be the lateralization index (Lik) of nodal degree (k) in the paracentral lobules ipsilateral and contralateral to the stroke lesion. The Lik will be used to quantify the relative distribution of nodal connectivity between the two hemispheres.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Difference in the Lateralization Index of Activation in the Sensorimotor Cortex Derived From fNIRS Data
Tidsramme: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

The lateralization index of cortical activation in the sensorimotor cortex will be calculated from functional near-infrared spectroscopy (fNIRS) data collected during walking. The outcome measure will assess the difference in the lateralization of sensorimotor cortical activation between robot-assisted gait rehabilitation and conventional gait rehabilitation following botulinum toxin type A treatment of spasticity in the triceps surae. Higher or lower lateralization index values will indicate a relative predominance of activation in one cerebral hemisphere.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Lateralization of Brain Activation in Locomotor-Related Cortical Areas During Walking
Tidsramme: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

The lateralization of brain activation in cortical areas involved in locomotion, including the prefrontal cortex (PFC), premotor cortex (PMC), and supplementary motor area (SMA), will be assessed during walking using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Differences in the lateralization of cortical activation between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups will be evaluated following botulinum toxin type A treatment of spasticity in the triceps surae.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks
Change in Resting-State Activity of the Ipsilesional Posterior Parietal Cortex
Tidsramme: Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Resting-state functional magnetic resonance imaging (rs-fMRI) will be used to assess changes in activity of the posterior parietal cortex ipsilateral to the stroke lesion. The change in resting-state activity will be compared between the robot-assisted gait rehabilitation and conventional gait rehabilitation groups following botulinum toxin type A treatment of spasticity in the triceps surae.

Baseline, at 5 weeks, at 12 weeks, at 17 weeks and at 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. desember 2026

Primær fullføring (Antatt)

1. juni 2029

Studiet fullført (Antatt)

1. juni 2029

Datoer for studieregistrering

Først innsendt

10. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2025

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2025-A01470-49
  • 2025-A01470-49 (Annen identifikator: ANSM)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .